Allied Biotech Corporation (1780) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Allied Biotech Corporation TWD 21.25, price TWD 24.85, upside -14.5%, quality 74 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Allied Biotech Corporation for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 10.44 TWD – 34.64 TWD · fair‑value band 15.03 TWD – 27.62 TWD · the 24.85 TWD price screens above the 21.25 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Allied Biotech in your weekly email
Every Wednesday you see whether Allied Biotech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Allied Biotech Corporation engages in the manufacture and sale of carotenoids worldwide.
Show more
Allied Biotech Corporation engages in the manufacture and sale of carotenoids worldwide. The company's products include Beta-Carotene that offers yellow to reddish orange shades to appeal color in various applications; Beta-Apo-8'-Carotenal, which is used as a food colorant, and provides a range of orange to red shades; and Lycopene, which offers a range of red shades as a nutrient for food, dietary supplements, and pharmaceutical products. It also provides Canthaxanthin, which offers a range of shades of reddish orange for food and beverage applications; Lutein, a carotenoid that provides a range of green leafed vegetables, such as spinach, kale, broccoli, and egg yolks.; and Nano Coenzyme Q10, an antioxidant, which is used in the transformation of energy in the body. It serves food, beverage, dietary supplement, and feed industries. The company was founded in 2001 and is headquartered in Taipei, Taiwan.
Stock analysis
Allied Biotech Corporation (1780) currently trades at 24.85 TWD, while our model-based Fair Value estimate is 21.25 TWD, implying the stock looks roughly 16.9% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 26.61 TWD per share, and 9 of the 24 models we run sit above the 24.85 TWD price.
Bear case: the Earnings-Based group reads lowest at 6.40 TWD, and 15 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: 15.03 TWD (bear) to 27.62 TWD (bull), the price of 24.85 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 74/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Allied Biotech Corporation reported revenue of 850M TWD in FY2025 versus 677M TWD in FY2021, a compound +5.8%/yr. Reported net income was 129M TWD in FY2025, compounding +77.5%/yr from FY2021. FY2021 was a trough year, so the rate overstates the trend.
Key figures
Market cap 2.4B TWD (≈ $75.1M) · P/E ratio 18.5 · P/S ratio 2.83 · EPS (TTM) 1.34 TWD · Dividend yield 5.0% · Net margin 15.2% · Return on equity 8.5% · Return on assets (EBIT) 4.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 28% below its 52-week high and 52% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −14%, 1780 screens richer than that median.
Fair Value models
Bear 15.03 TWDFair Value 21.25 TWDBull 27.62 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.0658 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.78/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+5.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.6%
Start year 2020 (pandemic). Over 10 years: +4.9% a year
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+15.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+10.1%
Dividend (yield on the price)5.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.10% vs 12%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.17% → 14%
Start year 2020 (pandemic)
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+4.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +2.4% a year for the price.
Compare Allied Biotech Corporation with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 626 stocks
Beats the industry median on 11/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score74 · Top 25%
Fair Value upside−15% · Below median
Profitability
Return on equity (TTM)8% · Above median
Return on assets4% · Above median
Net margin (TTM)12% · Above median
Operating margin (TTM)17% · Above median
Growth and dividend
Revenue growth15% · Above median
Dividend yield (TTM)5.0% · Top 25%
Balance sheet
Debt / equity0.03× · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Allied Biotech Corporation (1780) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 21.25 TWD versus a price of 24.85 TWD, about −14% upside (overvalued).
What is the fair value of 1780?
Our model-based fair value for Allied Biotech Corporation is 21.25 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 24.85 TWD.
What is the quality score of 1780?
Allied Biotech Corporation has a Quality Score of 74/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Allied Biotech Corporation (1780)?
Our model-based price target is the fair value of 21.25 TWD (as of Sep 24, 2026) from 24 valuation models. Cautious scenario 15.03 TWD, optimistic scenario 27.62 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Allied Biotech Corporation stock forecast for 2026?
Our models put fair value at 21.25 TWD, about −14% upside versus a price of 24.85 TWD (overvalued). Cautious scenario 15.03 TWD, optimistic scenario 27.62 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Allied Biotech Corporation (1780)?
Allied Biotech Corporation reported trailing-twelve-month revenue of about 880M TWD (latest available figure, as of Sep 24, 2026).
Does Allied Biotech Corporation pay a dividend?
Allied Biotech Corporation currently shows a dividend yield of about 5.03% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Allied Biotech Corporation (1780)?
For today's price to be fair in a discounted-cash-flow model, Allied Biotech Corporation would have to grow free cash flow by +4.0 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +6.6 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 1780 use?
Our models discount Allied Biotech Corporation at 11.8 %: a base by market capitalisation (micro), damped by beta 0.17, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Allied Biotech Corporation that is +4.0 % per year a year over ten years, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has Allied Biotech Corporation (1780) delivered so far?
Over the past 5 years revenue at Allied Biotech Corporation grew +6.6 % a year. The price currently implies +4.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Allied Biotech Corporation (1780) growing?
The median revenue growth in the sector is +0.0 % a year. That is the yardstick for the growth priced into Allied Biotech Corporation (+4.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Allied Biotech Corporation (1780)?
The free-cash-flow yield on the price is 7.67 %: that much free cash flow Allied Biotech Corporation produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Allied Biotech Corporation (1780)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Allied Biotech Corporation it is 21.25 TWD per share (as of Sep 24, 2026), against a price of 24.85 TWD. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Allied Biotech Corporation stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 1780 trades above its calculated fair value: price 24.85 TWD, fair value 21.25 TWD, a gap of about −14% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1780?
No. The price is what the market pays today (24.85 TWD); the fair value is what the company's own numbers justify (21.25 TWD). For Allied Biotech Corporation the two are 3.60 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Allied Biotech Corporation worth?
The market values Allied Biotech Corporation at about 2.4B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 24.85 TWD; our models calculate a fair value of 21.25 TWD per share.
What do the bullish and bearish scenarios say about 1780?
Our models span a range for Allied Biotech Corporation: cautious scenario 15.03 TWD, base 21.25 TWD, optimistic 27.62 TWD per share (as of Sep 24, 2026, price 24.85 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1780?
Allied Biotech Corporation trades at a price-to-earnings ratio of 18.5 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 21.25 TWD is built from several models across several years. Other multiples: P/B 1.9, P/S 2.7, EV/EBITDA 8.8.
How solid is the balance sheet of Allied Biotech Corporation (1780)?
Balance-sheet figures for Allied Biotech Corporation (as of Sep 24, 2026): return on equity 8.5%, debt of 0.03 per unit of equity. They feed the Quality Score of 74/100, which measures business quality independently of the share price.
How far is 1780 from its 52-week high?
Allied Biotech Corporation trades at 24.85 TWD, about 28% below its 52-week high of 34.64 TWD and 52% above the low of 16.31 TWD (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 21.25 TWD is for.
Which stocks are comparable to Allied Biotech Corporation?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Allied Biotech Corporation stock attractive at the current price?
The data as of Sep 24, 2026: price 24.85 TWD, calculated fair value 21.25 TWD (−14%), Quality Score 74/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1780 calculated?
We run Allied Biotech Corporation through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 21.25 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Allied Biotech Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Allied Biotech Corporation (1780)?
The closing price on Sep 23, 2026 was 24.85 TWD. Our model-based fair value is 21.25 TWD, about −14% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Allied Biotech Corporation right now?
A fairly wide model range (15.03 TWD to 27.62 TWD) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Where does the earnings growth of Allied Biotech Corporation (1780) come from?
Earnings per share at Allied Biotech Corporation grew +21.3 % a year from 2013 to 2024. Broken into its drivers: revenue per share +4.6 %, EBIT margin +12.0 %, tax rate −0.6 %, residual (interest, one-offs) +4.2 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Allied Biotech Corporation
How large is the market capitalisation of Allied Biotech Corporation (1780)?
The market capitalisation of Allied Biotech Corporation is 2.4B TWD (≈ $75.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Allied Biotech Corporation (1780)?
The price-to-sales ratio of Allied Biotech Corporation is 2.83 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Allied Biotech Corporation (1780)?
Earnings per share at Allied Biotech Corporation are 1.34 TWD (price ÷ EPS = P/E 18.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Allied Biotech Corporation (1780)?
The dividend yield of Allied Biotech Corporation is 5.0% (payout 93.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Allied Biotech Corporation (1780)?
The net margin of Allied Biotech Corporation is 15.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Allied Biotech Corporation (1780)?
The return on equity (ROE) of Allied Biotech Corporation is 8.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Allied Biotech Corporation (1780)?
On an EBIT basis the return on assets of Allied Biotech Corporation is 4.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Allied Biotech Corporation (1780)?
The operating margin of Allied Biotech Corporation is 16.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Allied Biotech Corporation (1780)?
Revenue at Allied Biotech Corporation is growing +14.6% versus a year earlier (3y avg +5.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Allied Biotech Corporation (1780)?
Earnings per share at Allied Biotech Corporation are growing −36.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Allied Biotech Corporation (1780) hold?
Allied Biotech Corporation holds more cash than debt, 23.0M TWD net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Allied Biotech Corporation in the live analysis
One click puts Allied Biotech Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
